Sat.Aug 29, 2020 - Fri.Sep 04, 2020

article thumbnail

10 reasons why virtual collaboration and medical education will persist in the new normal

pharmaphorum

While the effects of COVID-19 have been devastating for many industries, its positive impact on accelerating the uptake of digital health technologies and virtual collaboration solutions is undeniable. This has been a long time coming and there are countless reasons why I believe virtual collaboration and medical education are here to stay, long after there is a vaccine for COVID-19 and physical distancing guidelines have been lifted. 1.

article thumbnail

COVID-19 treatment study predicts adverse drug events

Outsourcing Pharma

Innovative research by Tabula Rasa Healthcare uses simulation technology to analyze potential adverse drug events of potential therapies for the virus.

96
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Medical Device Innovation Summit: India is poised to be a manufacturing hub for medical equipments and devices

Pharma Mirror

The first digital session of Medical Device Innovation Summit concludes on a positive note with industry leaders addressing burning topics to promote innovation in the medical equipment industry. From challenges like lack of regulatory systems to its new found potential of manufacturing indigenous products on a large scale, the summit successfully addressed discussions on new.

80
article thumbnail

Cheap Imodium alternative | Generic loperamide

Druggist

Without a doubt, Imodium is the most popular brand used as diarrhoea relief medication. Today’s post focuses on Imodium alternative drugs for the relief of diarrhoea. Causes of diarrhoea Diarrhoea is a common condition, which can affect children and adults of any age. A ‘stomach bug’ often causes acute diarrhoea, but an underlying condition and drugs can also cause it.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

MHRA publishes guidance on medicine regulation after Brexit

pharmaphorum

The UK’s medicines regulator has published long-awaited guidance on regulation of medicines and medical devices as the UK approaches the end of its Brexit transition period at the end of the year. This would see the UK mirroring decisions made by the European Medicines Agency, while also laying out a process should companies wish to file for a separate approval in the UK.

article thumbnail

Front-line physicians offer COVID-19 insights

Outsourcing Pharma

A recent study from healthcare insights company Sermo shares information and perspectives that trial and pharma professionals could learn from.

92

More Trending

article thumbnail

Video: A Major Driver of U.S. Digital Display Ad Spending Growth in 2020 and Beyond

Pharma Marketing Network

Despite the COVID-19 pandemic, digital display advertising will continue to grow this year with more investments in video ads. According to eMarketer, U.S. advertisers will increase investments in video by 11.3% this year to $35.45 billion, making it the only digital ad format to grow at a double-digit rate this year. For the first time ever, video will account for more than a quarter of all U.S. digital ad spending.

52
article thumbnail

Mobio closes $1.8m seed fund to develop meditation app

pharmaphorum

Digital health firm Mobio Interactive has closed a $1.8 million seed fund to advance development of its meditation app Am Mindfulness. Mobio said that the app, known as Am for short, is the first and only meditation app to outperform placebo in randomised controlled trials. MI’s Seed raise was led by the Singapore-based Verge HealthTech Fund along with Atlas Asset Management , Creative Ventures and VC giant SOSV.

122
122
article thumbnail

COVID-19 report shares insights on potential therapies

Outsourcing Pharma

A new scientific report offers a comprehensive review of protein targets, associated COVID-19 drug candidates to date and other revealing information.

72
article thumbnail

Not All Statins Interact With Grapefruit Juice

Med Ed 101

Drug food interactions are common and there can be significant negative consequences from these interactions. A common misconception amongst healthcare professionals who may not have as much experience with drug interactions is that ALL statins interact with grapefruit juice. I have heard and read this type of comment before, and it is not true. Grapefruit […].

40
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

PhIII US trial for AZ' coronavirus vaccine

Pharma Times

Clinical development of AZD1222 is progressing globally with late-stage clinical trials ongoing in the UK, Brazil and South Africa

article thumbnail

GSK opens £10m AI hub in London

pharmaphorum

GlaxoSmithKline is opening a £10 million artificial intelligence (AI) research hub in King’s Cross, London, according to a press report. The area is being reimagined as a life sciences and technology hub and is already home to the Francis Crick Institute biomedical research organisation. King’s Cross is also home to Google’s DeepMind artificial intelligence company, which has already been involved in life sciences projects such as using the technology to predict acute kidney injury.

114
114
article thumbnail

Elligo: increasing diversity can elevate trials

Outsourcing Pharma

A company leader outlines the importance of increasing diversity in clinical trial patient populations, and how researchers can improve their results.

67
article thumbnail

Paroxetine in Pregnancy – Why not?

Med Ed 101

If you are a healthcare professional, inevitably, questions about the use of antidepressants in pregnancy come up in clinical practice. Why is paroxetine generally avoided in pregnancy? The primary reason that paroxetine is avoided in pregnancy is that it has demonstrated fetal risks. Through the previous FDA rating system, it was considered an FDA pregnancy […].

FDA 40
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Immunotherapies could target aggressive pancreatic cancer, research indicates

Pharma Times

Scientists have discovered that hard-to-treat pancreatic cancer hijacks a key immune system response

article thumbnail

Highlight Therapeutics trials second-line melanoma combo after immunotherapy fails

pharmaphorum

Cancer immunotherapy has set new standards in care, with some impressive responses in those patients lucky enough to respond. But many patients still do not respond to therapies such as Merck & Co’s anti PD-1 therapy Keytruda (pembrolizumab), or go on to develop progressive disease, and pharma companies are looking for new second-line therapies.

article thumbnail

IntelGenx, ATAI partner on film-based psychedelics

Outsourcing Pharma

The companies will join forces to use IntelGenxâs polymeric film technologies for development of pharmaceutical-grade psychedelic drug treatments.

59
article thumbnail

Sanofi/Regeneron’s Kevzara fails again in serious COVID-19 cases

pharmaphorum

Sanofi has drawn another blank in its attempt to repurpose its IL-6 drug Kevzara to tackle the extreme immune reaction seen in serious cases of COVID-19. The French pharma and development partner Regeneron have been testing Kevzara (sarilumab) in patients severely or critically ill and hospitalised with COVID-19. In severe cases of COVID-19, patients suffer a “cytokine storm” where the immune system becomes overstimulated and attacks the body.

article thumbnail

Sanofi and GSK begin clinical trials of coronavirus vaccine

pharmaphorum

Sanofi and GlaxoSmithKline have begun clinical trials of their coronavirus vaccine, as AstraZeneca expanded studies of its rival into Japan. The French pharma in April joined forces with the UK’s GSK to produce the vaccine, with Sanofi contributing an antigen that produces the immune reaction. Meanwhile GSK is producing the booster that reduces the amount of active ingredient necessary to produce an effect.

Vaccines 106
article thumbnail

England trials population testing for COVID-19

pharmaphorum

England is to trial population testing for COVID-19 in places such as schools, colleges and busy public spaces. Health secretary Matt Hancock said the government has earmarked an extra £500 million ($552 million) to scale up testing and capacity to launch community pilots as fears mount about as second wave of infections during the winter months. The population testing will be made possible by new test kits capable of giving results within 15 minutes or so.

article thumbnail

How a flock of birds can help solve complex healthcare market research challenges

pharmaphorum

Bilal Babar from THE PLANNING SHOP tells us how the movement of birds and Swarm Technology have helped develop multiple market research tools. Flocks of birds wheeling, swooping and gliding in unison, as if choreographed, are a wonderful sight. The benefit to members of the flock are many including safety from predators, more eyes to spot food and natural selection – those that can’t keep up or fly in a very densely populated flock and make such sharp turns without colliding don’t survive.

article thumbnail

AZ expands phase 3 trials of COVID-19 vaccine frontrunner into US

pharmaphorum

AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups. The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response. AZ already has late-stage trials ongoing in the UK, Brazil and South America, with trials planned to start in Japan and Russia, recruiting up to 50,000 patients globally.

article thumbnail

AI tool looks to provide personalised COVID care

pharmaphorum

Microsoft and UK clinical AI company Sensyne Health will use their SENSE clinical algorithms to help provide more personalised care for COVID-19 patients as part of a new agreement with Chelsea & Westminster Hospital. SENSE is a clinical algorithm engine that generates AI algorithms (called SYNEs) for real-time decision support across multiple medical conditions. .

article thumbnail

BioXcel’s phase 3 schizophrenia film has blockbuster potential, say analysts

pharmaphorum

A sublingual film for acute agitation in schizophrenia and bipolar disorder from BioXcel has blockbuster potential that could pose a threat to an inhaled rival from Galen, according to analysts. Investment bank Jefferies ran the books on the company’s $69 million IPO in July and its analysts think that its AI-identified drug dexmedetomidine is likely to be approved thanks to “robust” phase 3 data and the drug’s rapid effects.

article thumbnail

EU regulators begin fast review of dexamethasone for COVID-19

pharmaphorum

European regulators have begun a speedy review of dexamethasone as a treatment for adults hospitalised with COVID-19, a potentially cheaper option to aid recovery than Gilead’s Veklury. Dexamethasone is a generic steroid that has been repurposed as a treatment for COVID-19, where it has been shown to alleviate the severe respiratory complications seen with the disease.

59
article thumbnail

Canada signs deals for J&J, Novavax COVID vaccines

pharmaphorum

The Canadian government has reached agreements in principle with J&J and Novavax to buy their coronavirus vaccine candidates. Under the agreement with J&J, Canada would purchase up to 38 million doses of Janssen’s Ad26.COV2.S vaccine candidate on a not-for-profit basis for emergency pandemic use. Meanwhile, Novavax has agreed to supply up to 76 million doses of its candidate in the event of the vaccine gaining approval in the country.

article thumbnail

Registration opens for Pre-filled Syringes & Injectable Devices Conference 2021

pharmaphorum

SMi Reports: Registration is open for SMi Group’s 13 th annual conference and exhibition taking place in January 2021. The pre-filled syringes industry is growing at an exponential rate. With increasing demand for self-administration, a rise in biologics, large-volume delivery and the delayed EU MDR at the forefront of the field, SMi’s 13th annual event will bring you the key insights you need to grow and enhance your pre-filled syringes portfolio and discover what the future holds for the PFS a

article thumbnail

Behavioural insights into haem/onc clinical decision-making

pharmaphorum

With exclusive surveys of the continuing medical education (CME) needs of haematologists/oncologists (haem/oncs), this webinar will look at where physicians are going for their learning needs and what effect the COVID-19 pandemic continues to have. The Behavioural insights into haem/onc clinical decision-making webinar, in association with Medscape, will take place on Thursday 3rd September from 13:00-14:00 (BST)/14:00-15:00 (CEST).

52
article thumbnail

Why switch to automated CRF annotations?

pharmaphorum

What is an annotated CRF? Annotated CRF’s document the location in a database of the data collected for each question on a form. In other words, it’s a mapping between each item on a form to its corresponding variable contained within the corresponding dataset. Annotated CRFs are part of the mandatory CDISC submission deliverables to the FDA. So they’re a must!

article thumbnail

Protein Misfolding Drug Discovery Summit

pharmaphorum

With protein misfolding and aggregation prevalent in neurodegeneration, cancer, metabolic and ophthalmic diseases, the unmet clinical need presents huge opportunity to accelerate the discovery and translation of novel therapeutics to transform patient outcomes. However, despite decades of clinical lessons, revived investment and scientific progress in understanding the molecular biology of protein misfolding disorders, there are still currently no approved disease-modifying therapies or cures av

52
article thumbnail

White paper helps industry navigate new NHS roadmap

pharmaphorum

As the pandemic response in the UK moves on to ‘phase 3’, and the NHS plans to make a gradual return to pre-Covid-19 service levels, pharma must define how its products and services fit into the new roadmap that has been created. In a bid to answer some of these questions for industry, healthcare intelligence provider Wilmington Healthcare has published a white paper, entitled “Covid-19: Roadmap to Recovery”.

article thumbnail

3rd Lab Asset & Facility Management in Pharma Summit

pharmaphorum

The 3rd Lab Asset & Facility Management in Pharma will return this Winter as your ONLY industry led meeting focusing on R&D asset and FM, enabling you to regain control of your assets , optimize your space and benchmark best practices to stay ahead of the curve. For this year only, guests from pharma, biotech & academic institutions can attend for FREE !

52
article thumbnail

AZ trumpets Farxiga survival data in renal disease at ESC 2020

pharmaphorum

AstraZeneca’s Farxiga is already ahead of rivals in the SGLT2 inhibitor field in heart failure, and now looks set to repeat that success in renal disease after reporting stellar results from the DAPA-CKD trial. AZ halted DAPA-CKD in July after revealing that Farxiga (dapagliflozin) met its objective of slowing the worsening of renal function and cut the risk of death in patients with chronic kidney disease (CKD) with and without type 2 diabetes. .

FDA 52
article thumbnail

3rd RNA-Targeted Drug Discovery Summit

pharmaphorum

The 3rd RNA- Targeted Drug Discovery Summit returns as the most comprehensive and definitive event for the RNA targeting small molecule community to not only address key challenges of the field, such as successful determination and prediction of RNA structure and role in disease, but also to drive forward optimized strategies to improve target selection and gain pre-clinical proof of concept to drive the field forward towards translation into clinical development.

52